MA48870B1 - Anticorps anti-sortiline et leurs méthodes d'utilisation - Google Patents
Anticorps anti-sortiline et leurs méthodes d'utilisationInfo
- Publication number
- MA48870B1 MA48870B1 MA48870A MA48870A MA48870B1 MA 48870 B1 MA48870 B1 MA 48870B1 MA 48870 A MA48870 A MA 48870A MA 48870 A MA48870 A MA 48870A MA 48870 B1 MA48870 B1 MA 48870B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- sortlin
- compositions
- sortilin antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne d'une manière générale des compositions qui comprennent des anticorps, par exemple des anticorps monoclonaux, chimériques, à maturation d'affinité, humanisés, des fragments d'anticorps, etc., qui se lient spécifiquement à une protéine sortiline, par exemple une sortiline humaine ou une sortiline de mammifère, et qui présentent des caractéristiques fonctionnelles améliorées et/ou accrues, et l'utilisation de telles compositions dans la prévention, la réduction des risques, ou le traitement d'un individu qui en a besoin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862698007P | 2018-07-13 | 2018-07-13 | |
PCT/US2019/041614 WO2020014617A1 (fr) | 2018-07-13 | 2019-07-12 | Anticorps anti-sortiline et leurs méthodes d'utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
MA48870A MA48870A (fr) | 2020-04-01 |
MA48870B1 true MA48870B1 (fr) | 2023-03-31 |
Family
ID=83218695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA48870A MA48870B1 (fr) | 2018-07-13 | 2019-07-12 | Anticorps anti-sortiline et leurs méthodes d'utilisation |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR122237A1 (fr) |
MA (1) | MA48870B1 (fr) |
-
2019
- 2019-07-12 AR ARP190101981A patent/AR122237A1/es unknown
- 2019-07-12 MA MA48870A patent/MA48870B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AR122237A1 (es) | 2022-08-31 |
MA48870A (fr) | 2020-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54405B1 (fr) | Anticorps de la glycoprotéine de spicule anti-sras-cov-2 et fragments de liaison à l'antigène | |
MA40801A1 (fr) | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 | |
MA33387B1 (fr) | Polypeptides et procede de traitement | |
EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
MA35345B1 (fr) | Proteines de liaisons a un antigene ayant une liaison accrue a fcrn | |
MA44312A (fr) | Anticorps et leurs méthodes d'utilisation | |
TNSN04078A1 (fr) | Antibodies to cd40 | |
MA35174B1 (fr) | Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines | |
MA33402B1 (fr) | Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps | |
MA42935B1 (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
MA40041A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
MA45125B1 (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA29374B1 (fr) | Anticorps anti-ccr5 et leurs utilisations | |
MA31899B1 (fr) | Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant | |
MA30876B1 (fr) | Anticorps de la lymphotoxine-alpha | |
MA54975B1 (fr) | Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation | |
EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
EA201992688A1 (ru) | Средства, пути применения и способы лечения | |
MA48870B1 (fr) | Anticorps anti-sortiline et leurs méthodes d'utilisation | |
MA48241A1 (fr) | Anticorps dirigés contre madcam | |
MA53186B2 (fr) | Anticorps monoclonal qui se lie spécifiquement à cd20 | |
MA47976B1 (fr) | Anticorps dirigés contre trem2 et leur utilisation | |
MX2021003867A (es) | Anticuerpo monoclonal beta amiloide anti-n-truncado humanizado. | |
MA33668B1 (fr) | Anticorps chimériques spécifiques pour cd151 et leur utilisation dans le traitement du cancer | |
MA51717A1 (fr) | Anticorps anti-cd63, conjugués et leurs utilisations |